Meeting
2019 Gastrointestinal Cancers Symposium
Tislelizumab in combination with chemotherapy in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer: Results from one cohort of an ongoing phase 2 study.
Authors
Yu-Xian Bai
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
Yu-Xian Bai , En Xiao Li , Buhai Wang , Xianglin Yuan , Nong Xu , Yunxin Chen , Xiang Li , Huanli Wang , Jianming Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT03469557
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 11)
DOI
10.1200/JCO.2019.37.4_suppl.11
Abstract #
11
Poster Bd #
E1
Abstract Disclosures
Similar Posters
First Author: Keun Wook Lee
Poster
2021 ASCO Annual Meeting
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Keun Wook Lee
Poster
2020 ASCO Virtual Scientific Program
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Do-Youn Oh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
First Author: Zev A. Wainberg